文献速递生殖医学

辅助卵母细胞激活不能克服复发性胚胎发育问题

Assisted oocyte activation does not overcome recurrent embryo developmental problems.
PubMed 文献 · Hum Reprod · 2023-01-01

本前瞻性单中心队列研究纳入42对既往至少两次ICSI周期受精率正常(≥60%)但胚胎发育受损(囊胚形成率≤15%)的夫妇,其中17对接受ICSI-AOA周期,与同一队列的44个既往ICSI周期比较,AOA未改善囊胚形成率,全外显子测序发现部分患者存在SCMC基因变异。

要点

  • AOA未改善复发性胚胎发育问题患者的囊胚形成率(13.74% vs 9.35%,P=0.18)。
  • AOA后总受精率、妊娠率、活产率与既往ICSI周期无显著差异。
  • 部分患者检出SCMC基因意义未明变异,一例男性检出PLCZ1纯合突变。

核心结论

  • AOA未能改善本队列中复发性胚胎发育问题患者的囊胚形成。

研究设计与样本

  • 前瞻性单中心队列研究,2018年1月至2021年1月纳入42对既往至少两次ICSI周期受精率正常(≥60%)但胚胎发育受损(囊胚形成率≤15%)的夫妇,其中17对接受ICSI-AOA周期(CaCl2注射联合双次离子霉素暴露),与同一队列的44个既往ICSI周期比较,并进行小鼠卵母细胞钙分析及全外显子测序。

主要发现

  • AOA后总受精率68.95%(131/190) vs 既往ICSI周期76.25%(321/421),P=0.06。
  • AOA后囊胚形成率13.74%(18/131) vs 既往ICSI周期9.35%(30/321),P=0.18。
  • AOA后妊娠率29.41%(5/17) vs 既往ICSI周期25.00%(11/44),P=0.75。
  • AOA后活产率23.53%(4/17) vs 既往ICSI周期15.91%(7/44),P=0.48。
  • 遗传筛查发现14例女性携带NLRP2、NLRP5、NLRP7、TLE6和PADI6的意义未明杂合变异,一例男性检出PLCZ1纯合突变c.1499C>T(p.Ser500Leu)。

临床怎么用

  • 作者认为AOA应保留用于存在明确钙释放缺陷的夫妇。
  • 作者认为全外显子测序可能发现与胚胎发育问题相关的新基因和变异,并设计更个性化的治疗选择,如野生型补充RNA或重组蛋白注射。

局限性

  • 严格的纳入标准要求至少两次ICSI周期胚胎发育受损,减少了周期间的变异性,但要求较低的囊胚发育率不受差受精影响,排除了原本可能选择AOA的夫妇,限制了样本量。
  • 靶向遗传筛查可能过于局限,无法识别所有患者胚胎发育不良表型的遗传原因。
  • 所识别意义未明变异的因果关系需进一步确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Can recurrent embryo developmental problems after ICSI be overcome by assisted oocyte activation (AOA)? SUMMARY ANSWER: AOA did not improve blastocyst formation in our patient cohort with recurrent embryo developmental problems after ICSI. WHAT IS KNOWN ALREADY: The use of AOA to artificially induce calcium (Ca2+) rises by using Ca2+ ionophores (mainly calcimycin and ionomycin) has been reported as very effective in overcoming fertilization failure after ICSI, especially in patients whose Ca2+ dynamics during fertilization are deficient. However, there is only scarce and contradictory literature on the use of AOA to overcome embryo developmental problems after ICSI, and it is not clear whether abnormal Ca2+ patterns during fertilization disturb human preimplantation embryo development. Moreover, poor embryo development after ICSI has also been linked to genetic defects in the subcortical maternal complex (SCMC) genes. STUDY DESIGN, SIZE, DURATION: This prospective cohort single-center study compared ICSI-AOA cycles and previous ICSI cycles in couples with normal fertilization rates (≥60%) but impaired embryonic development (≤15% blastocyst formation) in at least two previous ICSI cycles. In total, 42 couples with embryo developmental problems were included in this study from January 2018 to January 2021. PARTICIPANTS/MATERIALS, SETTING, METHODS: Of the 42 couples included, 17 underwent an ICSI-AOA cycle consisting of CaCl2 injection and double ionomycin exposure. Fertilization, blastocyst development, pregnancy, and live birth rates after ICSI-AOA were compared to previous ICSI cycles. In addition, the calcium pattern induced by the male patient's sperm was investigated by mouse oocyte calcium analysis. Furthermore, all 42 couples underwent genetic screening. Female patients were screened for SCMC genes (TLE6, PADI6, NLRP2, NLRP5, NLRP7, and KHDC3L) and male patients were screened for the sperm-oocyte-activating factor PLCZ1. MAIN RESULTS AND THE ROLE OF CHANCE: We compared 17 AOA cycles to 44 previous ICSI cycles from the same patient cohort. After AOA, a total fertilization rate of 68.95% (131/190), a blastocyst development rate of 13.74% (18/131), a pregnancy rate of 29.41% (5/17), and a live birth rate of 23.53% (4/17) were achieved, which was not different from the previous ICSI cycles (76.25% (321/421, P-value = 0.06); 9.35% (30/321, P-value = 0.18), 25.00% (11/44, P-value = 0.75), and 15.91% (7/44, P-value = 0.48), respectively). Calcium analysis showed that patient's sperm induced calcium patterns similar to control sperm samples displaying normal embryo developmental potential. Genetic screening revealed 10 unique heterozygous variants (in NLRP2, NLRP5, NLRP7, TLE6, and PADI6) of uncertain significance (VUS) in 14 females. Variant NLRP5 c.623-12_623-11insTTC (p.?) was identified in two unrelated individuals and variant NLRP2 c.1572T>C (p.Asp524=) was identified in four females. Interestingly, we identified a previously reported homozygous mutation PLCZ1, c.1499C>T (p.Ser500Leu), in a male patient displaying impaired embryonic development, but not showing typical fertilization failure. LIMITATIONS, REASONS FOR CAUTION: Our strict inclusion criteria, requiring at least two ICSI cycles with impaired embryo development, reduced cycle-to-cycle variability, while the requirement of a lower blastocyst development not influenced by a poor fertilization excluded couples who otherwise would be selective cases for AOA; however, these criteria limited the sample size of this study. Targeted genetic screening might be too restricted to identify a genetic cause underlying the phenotype of poor embryo development for all patients. Moreover, causality of the identified VUS should be further determined. WIDER IMPLICATIONS OF THE FINDINGS: Strong evidence for AOA overcoming impaired embryonic development is still lacking in the literature. Thus far, only one article has reported a beneficial effect of AOA (using calcimycin) compared to previous ICSI cycles in this patient population, whilst two more recent sibling-oocyte control studies (one using calcimycin and the other ionomycin) and our research (using ionomycin) could not corroborate these findings. Although no major abnormalities have been found in children born after AOA, this technique should be reserved for couples with a clear Ca2+-release deficiency. Finally, genetic screening by whole-exome sequencing may reveal novel genes and variants linked to embryo developmental problems and allow the design of more personalized treatment options, such as wild-type complementary RNA or recombinant protein injection. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by the Flemish Fund for Scientific Research (grant FWO.OPR.2015.0032.01 to B.H. and grant no. 1298722N to A.B.). A.C.B., D.B., A.B., V.T., R.P., F.M., I.D.C., L.L., D.S., P.D.S., P.C., and F.V.M. have nothing to disclose. B.H. reports a research grant from the Flemish Fund for Scientific Research and reports being a board member of the Belgian Society for Reproductive Medicine and the Belgian Ethical Committee on embryo research. TRIAL REGISTRATION NUMBER: NCT03354013.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Cardona Barberán A, Bonte D, Boel A, et al. Assisted oocyte activation does not overcome recurrent embryo developmental problems. Hum Reprod. 2023. PMID: 36931261. doi:10.1093/humrep/dead051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。